title: Danitumumab adjunctive therapy. No place in either first- or second-line treatment of metastatic colorectal cancer.
abstract: Adding panitumumab to standard protocols does not prolong survival but provokes additional adverse effects.
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D066246:ErbB Receptors; D006801:Humans; D007262:Infusions, Intravenous; D009362:Neoplasm Metastasis; D000077544:Panitumumab; D013534:Survival
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077544:Panitumumab; D066246:ErbB Receptors